BRIDGEBIO PHARMA, INC.

Lobbying for BRIDGEBIO PHARMA, INC. · Biotech company

Filing · LD-2 quarterly report Q4 amendment

Reporting period

4th Quarter 2023

Oct 1 - Dec 31 · Posted Jul 17, 2026

Expenses

$140,000

What this organization spent lobbying with its own staff. The filing did not state which of the three LDA accounting methods produced this number, so it is not comparable with another filer's.

Client based in

California

Official filing document

Government bodies contacted

House of Representatives
Senate

Only the chambers were recorded for this filing. Any agencies it named are in the official document.

Lobbying activity 1

Pharmacy

ORPHAN Cures Act H.R. 5539; S. 3131 Promising Pathways Act HR 4408; S. 1906 PAHPA H.R.469 PAHPA S.R. 2333 Innovation in Pediatric Drugs Act of 2023

Bills named in this filing 5

H.R. 5539
ORPHAN Cures Act
S. 3131
ORPHAN Cures Act
H.R. 4408
Promising Pathway Act
S. 1906
Promising Pathway Act
H.R. 469
Asylum Abuse Reduction Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.